Mice deficient in MLH1 develop lymphomas at a lower frequency compared to MSH2-/- mice [46], while mice with thymocyte-specific deletion of MLH1 develop lymphomas at a remarkably reduced frequency compared to MLH1-/- mice (6% vs 26%), and most of the lymphomas are double positive [46]. Here, MSH2 is linked to lymphoma.